Mesna Baxter Healthcare

Mesna, the active ingredient in Mesna Baxter Healthcare, is a uroprotective agent presented as an oral formulation for oral use. It protects the urinary tract epithelium from toxic metabolites generated during cyclophosphamide or ifosfamide chemotherapy, thereby reducing the risk of hemorrhagic cystitis in patients receiving these agents.

GNH USA supplies Mesna Baxter Healthcare as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Mesna is used as a chemoprotective agent to safeguard the urinary tract during chemotherapy that generates toxic metabolites.

- Cyclophosphamide therapy: prevents hemorrhagic cystitis associated with cyclophosphamide treatment. - Ifosfamide therapy: prevents hemorrhagic cystitis associated with ifosfamide treatment. - High‑dose chemotherapy regimens: reduces urinary tract toxicity by detoxifying acrolein.

Mesna is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Vomiting: occasional episodes of emesis. - Headache: transient cranial discomfort. - Metallic taste: altered taste perception. - Mild rash: limited skin erythema. - Dysuria: discomfort during urination.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis or angioedema. - Hematuria: visible blood in urine. - Acute renal failure: sudden loss of kidney function. - Pulmonary edema: fluid accumulation in lungs. - Stevens‑Johnson syndrome: severe skin and mucous membrane involvement. - Hepatotoxicity: elevated liver enzymes indicating liver injury.

Before prescribing Mesna, clinicians should consider several safety measures.

- Renal function assessment: evaluate baseline kidney function and monitor during therapy. - Hydration encouragement: ensure adequate fluid intake to promote urinary flushing. - Concomitant nephrotoxic drugs: avoid or closely monitor use with other kidney‑harmful agents. - Dose adjustment in renal impairment: modify regimen if creatinine clearance is reduced. - Patient counseling: inform about signs of urinary irritation or allergic reaction. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Mesna may interact with other medicines, influencing safety or efficacy.

Major Interactions (Avoid): - Concurrent high‑dose nephrotoxic agents: may increase risk of renal injury. - Sulfhydryl‑reactive drugs: can reduce Mesna's protective effect.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter urinary excretion of Mesna. - Antacids containing aluminum or magnesium: could affect absorption. - Warfarin: monitor INR as Mesna may influence anticoagulant control. - Methotrexate: watch renal function closely when both are used. - NSAIDs: increased potential for kidney stress.